COMPANY

DUB Therapeutics Inc.

Keywords: RNA therapeutics ophthalmology fibrosis siRNA

Profile checked Oct 10, 2026

NIH awards 5

Annual award amounts. Total $3.8M.

Sep 17, 2026 NIH award 5R44EY038138-02 FY2026: $1,009,284 awarded for that fiscal year; activity R44 (SBIR); PI WILLIAMS, TERE M.; recipient as written: DUB THERAPEUTICS INC., SYRACUSE, NY. A novel siRNA therapeutic to prevent sc source ↗
Sep 5, 2025 NIH award 1R44EY038138-01 FY2025: $1,009,285 awarded for that fiscal year; activity R44 (SBIR); PI WILLIAMS, TERE M.; recipient as written: DUB THERAPEUTICS INC., SYRACUSE, NY. A novel siRNA therapeutic to prevent sc source ↗
Sep 11, 2024 NIH award 3R44EY035188-02S1 FY2024: $182,000 awarded for that fiscal year; activity R44 (SBIR); PI WILLIAMS, TERE M.; recipient as written: DUB THERAPEUTICS INC., SYRACUSE, NY. A single dose anti-scarring therapeutic source ↗
Aug 20, 2024 NIH award 5R44EY035188-02 FY2024: $917,935 awarded for that fiscal year; activity R44 (SBIR); PI WILLIAMS, TERE M.; recipient as written: DUB THERAPEUTICS INC., SYRACUSE, NY. A single dose anti-scarring therapeutic f source ↗
Sep 19, 2023 NIH award 1R44EY035188-01 FY2023: $699,991 awarded for that fiscal year; activity R44 (SBIR); PI WILLIAMS, TERE M.; recipient as written: DUB THERAPEUTICS INC., SYRACUSE, NY. A single dose anti-scarring therapeutic f source ↗

NIH award NIH awarded $1.01M (SBIR Phase II 5R44EY038138-02, continuation, notice Sep 17, 2026). NIH RePORTER 5R44EY038138-02 (Sep 17, 2026)
Evidence (1 event)
- Sep 17, 2026 · NIH RePORTER 5R44EY038138-02
  Organization: DUB THERAPEUTICS INC.; City/State: SYRACUSE, NY; Project number: 5R44EY038138-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 1009284; Administering IC: National Eye Institute; Project title: A novel siRNA therapeutic to prevent scarring and bleb failure after trabeculectomy; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals